A new trading day began on Tuesday, with Humacyte Inc (NASDAQ: HUMA) stock price down -5.19% from the previous day of trading, before settling in for the closing price of $1.35. HUMA’s price has ranged from $1.15 to $6.77 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 42.43%. Meanwhile, its annual earnings per share averaged 70.33%. With a float of $152.67 million, this company’s outstanding shares have now reached $156.34 million.
Humacyte Inc (HUMA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Humacyte Inc is 18.47%, while institutional ownership is 28.64%. The most recent insider transaction that took place on Aug 19 ’25, was worth 1,793,000. In this transaction Director of this company sold 1,100,000 shares at a rate of $1.63, taking the stock ownership to the 591,685 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Director sold 549,360 for $1.83, making the entire transaction worth $1,005,329. This insider now owns 1,691,685 shares in total.
Humacyte Inc (HUMA) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.26 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.33% per share during the next fiscal year.
Humacyte Inc (NASDAQ: HUMA) Trading Performance Indicators
Here are Humacyte Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 292.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Humacyte Inc (HUMA)
The latest stats from [Humacyte Inc, HUMA] show that its last 5-days average volume of 4.91 million was superior to 4.28 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 18.45%.
During the past 100 days, Humacyte Inc’s (HUMA) raw stochastic average was set at 3.70%, which indicates a significant decrease from 10.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0982 in the past 14 days, which was lower than the 0.1539 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6409, while its 200-day Moving Average is $2.2287. Now, the first resistance to watch is $1.3400. This is followed by the second major resistance level at $1.4000. The third major resistance level sits at $1.4300. If the price goes on to break the first support level at $1.2500, it is likely to go to the next support level at $1.2200. The third support level lies at $1.1600 if the price breaches the second support level.
Humacyte Inc (NASDAQ: HUMA) Key Stats
With a market capitalization of 239.71 million, the company has a total of 158,372K Shares Outstanding. Currently, annual sales are 0 K while annual income is -148,700 K. The company’s previous quarter sales were 300 K while its latest quarter income was -37,660 K.
